Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT03816345
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +51 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Register for Updates
Assessment of Corneal Endothelial Function Following Hypoxic Stress
NCT04175938
Recruiting
The purpose of this study is to determine the difference in the cornea's response to contact lens placement between healthy and unhealthy eyes. The amount of corneal swelling (corneal thickness) between normal and FECD patients before and after a stress test will be measured and compared.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2025
Locations: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
Conditions: Fuchs' Endothelial Corneal Dystrophy
Register for Updates
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
NCT04440280
Recruiting
This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/17/2025
Locations: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts
Conditions: Fuchs Endothelial Corneal Dystrophy
Register for Updates
Surgical Resection of Latent Brain Tumors Prior to Recurrence
NCT04810871
Recruiting
This clinical trial evaluates the side effects and possible benefits of operating on brain tumors prior to the tumor coming back (recurrence). Understanding when surgery is most useful to patients with brain tumors is important. Some patients may undergo chemotherapy or radiation but still have visible tumor remaining after treatment. The purpose of this research is to compare outcomes of those who have surgery after chemotherapy or radiation, but prior to tumor recurrence, to those who have sur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Brain Neoplasm
Register for Updates
Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
NCT04948658
Recruiting
Background: Turner Syndrome, galactosemia, and premature ovarian insufficiency are all conditions that may make it very hard or impossible for a person to become pregnant and have their own child. Researchers want to learn more about why this happens and if freezing Gonadal tissue allows for fertility preservation. Objective: To find out why people with certain conditions have can have premature ovarian insufficiency (POI or early menopause) and individuals with variations in sex characterist... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
05/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Ovarian Disfunction, Post-menarcheal Adolescents, Turner Syndrome, Galactosemia, Variations in Sex Characteristics, Differences in Sex Development
Register for Updates
Human Immune Response to Ixodes Scapularis Tick Bites
NCT05036707
Recruiting
Background: Each year, the number of cases of tick-borne diseases increases. The deer tick (Ixodes scapularis) is the vector of at least 7 pathogens that cause human diseases, including Lyme disease. Researchers want to learn more to help them develop vaccines against ticks in the future. Objective: To learn how people s bodies, particularly the skin, respond to tick bites. Eligibility: Healthy adults aged 18 years and older who have no known history of a tick-borne disease or tick bite exp... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Tick-borne Diseases, Tick Resistance, Lyme Disease
Register for Updates
Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)
NCT05336786
Recruiting
This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/17/2025
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania +1 locations
Conditions: Prostate Carcinoma
Register for Updates
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
NCT05588128
Recruiting
Background: Prostate cancer is the second leading cause of cancer-related death in American men. The disease recurs in up to 50,000 men each year after their early-stage disease was treated; however, at this stage, imaging scans are often unable to find the disease in the body. In this natural history study, researchers want to find out if a new radiotracer (18F-DCFPyL) injected before positron emission tomography (PET) imaging can help identify sites in the body with cancer. Objective: To le... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer, Biochemically Recurrent
Register for Updates
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
NCT05627245
Recruiting
This phase I trial tests the safety, side effects, and best dose of combination therapy with tazemetostat and belinostat in treating patients with lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Tazemetostat is in a class of medications called EZH2 inhibitors. The EZH2 gene provides instructions for making a type of enzyme called histone methyltransferase which is involved in gene expression and cell division. Blocking EZH2... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2025
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California +9 locations
Conditions: Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Register for Updates
Towards a Wearable Alcohol Biosensor: Examining the Accuracy of BAC Estimates From New-Generation Transdermal Technology Using Large-Scale Human Testing and Machine Learning Algorithms
NCT05692830
Recruiting
The study will employ a combined laboratory-ambulatory design. Participants will engage in ambulatory assessment over the course of 14 days, wearing biosensors assessing transdermal alcohol concentration (TAC) and providing breathalyzer readings in real-world contexts. Also during this period, participants will attend three laboratory alcohol-administration sessions scheduled at one-week intervals, with alcohol dose and rate of consumption manipulated within and between participants, respectivel... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/17/2025
Locations: University of Illinois at Urbana-Champaign, Champaign, Illinois
Conditions: Alcohol Drinking, Alcohol Intoxication
Register for Updates
Evaluation of the Genetics of Bipolar Disorder
NCT00001174
Recruiting
This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/17/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Bipolar Disorder
Register for Updates
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128
Recruiting
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2025
Locations: Alabama Neurology Associates- Site Number : 8400019, Birmingham, Alabama +96 locations
Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Register for Updates